AI Powered Model to Predict Response to Intravesical BCG Versus Gem-Doce for HR NMIBC Vignesh Packiam, MD Valar Labs UroToday.com #SUO24 🎯 CHAI biomarker +ve: Predictive of ⬆️ HG-RFS in pts treated with Gem-Doce vs BCG ⚡️First AI-based histologic biomarker to predict clinical

"At the end you need to build a self-sustaining engine." Anirudh Joshi, #ForbesUnder30 lister, spoke about the power of cold calling and his advice to entrepreneurs looking to get their foot in the door. forbes.com/sites/alexknap…

📺 Amanda Nizam, MD speaks with Vignesh Packiam, MD about his innovative study on an AI-powered model designed to predict patient response to intravesical BCG in high-risk non-muscle invasive #bladdercancer: buff.ly/3W4nlU6

Our goals: New medicines. New practice of medicine. Our team: a16z's global venture capital platform, together with Eli Lilly and Company, the largest pharma company in the world. Go :) Excited about the opportunities ahead! cc Jorge Conde a16z Bio + Health statnews.com/2025/01/10/eli…

An #ArtificialIntelligence-powered predictive biomarker for response to intravesical BCG versus gemcitabine-docetaxel for high-grade #NMIBC. Presentation by Vignesh Packiam, MD Rutgers Cancer Institute. #AUA25 written coverage by Rashid K. Sayyid USC > bit.ly/4jQSrbg Amer. Urol. Assn.

Excited to share this paper which has been many years in the making! This is the first publication of a predictive (AI-histology based) biomarker to guide rational use of BCG vs Gem/Doce for newly diagnosed HG NMIBC pubmed.ncbi.nlm.nih.gov/40287344/ Curves say it all 👇🏾

We are thrilled to share our recent publication in European Urology Oncology demonstrating for the first time CHAI based predictive biomarker to guide use of intravesical BCG vs alternatives (chemotherapy). In an era of BCG shortage and new alternatives to BCG incoming, precision medicine

With a plethora of choices coming to bladder cancer management, being able to guide treatment decision making is critical for optimal patient outcomes. We are thrilled to demonstrate that Vesta, our flagship diagnostic in bladder cancer, can predict patients who would likely

Excited for our growing collaboration with Cleveland Clinic Urology and Valar Labs>> empowering our #BladderCancer patients with precision based evidence for their cancer care

Our recent publication in European Urology Oncology demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC. A critical step forward in precision intravesical therapy.

Grateful to collaborate with you Ashish M. Kamat, MD, MBBS !

Thrilled to be working together Vignesh Packiam, MD

Great conversation between Vignesh Packiam, MD and Sam S. Chang MD, MBA on our recent European Urology Oncology Publication describing the clinical utility of Vesta BCGPredict especially in an era of BCG shortage and new treatments to aid with selection of intravesical treatment Patrick Hensley, MD